Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies

Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products

Long, Proven Track Record of Successful Commercial Drug Product Manufacturing, Serving Both Large Pharma and Emerging Companies

GAINESVILLE, Ga., June 11, 2020 (GLOBE NEWSWIRE) -- Recro Gainesville, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today highlighted its readiness and available capacity to secure new oral drug product manufacturing contracts for its CDMO facilities in Gainesville, GA. In support of future commercial growth Recro Gainesville is installing a 400 liter high shear granulator and a 420 liter fluid bed dryer. Both will be operational in the fourth quarter of 2020. These additions are aligned with Recro’s strategy to provide end to end services from development to commercial in the oral solid dosage forms.  

Recro owns and operates a 97,000 square foot, DEA-licensed CDMO facility designed to provide customers with a broad range of CDMO services, from benchtop through commercialization. Recro’s facility houses development and manufacturing space focused on creating unique oral dosage forms, solving formulation, process and analytical issues, as well as clinical trial supply manufacturing and related services. Recro also operates a specialized, 24,000 square foot space with dedicated suite areas for high potency and for early stage drug product manufacturing.

“Recro has a 20-year track record of successful solid oral drug product manufacturing, including tablets, capsules, sustained-release and extended-release formulations, among others,” said Gerri Henwood, CEO of Recro.  “We also have a long, established history of on time, in full delivery of important development stage and commercial products and development milestones for large pharma and emerging life science companies.  As we work to navigate through these challenging times, Recro stands ready with our development and manufacturing expertise, broad capabilities and available U.S. capacity to serve our current clients and potential future customers.”